Want to see MMED full AI Analyst Report?
Top Page
MiniMed Group, Inc.
(NASDAQ:MMED)
Select Model
Select Model
Rating:55Neutral
Price Target:
$19.50
▼(-2.99% Downside)
Action:Reiterated
Date:10/16/26
The score is held back primarily by weak financial quality (widening losses and significantly worsening cash flow) and bearish technical momentum. These risks are partially offset by a strongly positive earnings call with raised revenue guidance, reaffirmed margin outlook, and visible product/pipeline milestones.
Positive Factors
Organic revenue growth
Strong organic growth across the U.S. and international markets indicates broad demand for MiniMed’s products rather than reliance on a single geography. Raised fiscal guidance supports the durability of the growth outlook and provides a foundation for operating leverage as scale increases.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow indicates that current operations are not yet funding the company’s investment needs. If cash conversion does not improve, MiniMed may face greater funding and execution pressure while continuing to scale its product platform.
Read all positive and negative factors
Positive Factors
Negative Factors
Organic revenue growth
Strong organic growth across the U.S. and international markets indicates broad demand for MiniMed’s products rather than reliance on a single geography. Raised fiscal guidance supports the durability of the growth outlook and provides a foundation for operating leverage as scale increases.
Read all positive factors
MiniMed Group, Inc. (MMED) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.42B
Dividend YieldN/A
Average Volume (3M)12.70M
Price to Earnings (P/E)―
Beta (1Y)0.38
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees8,000
SectorGeneral
Sector StrengthN/A
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)-1.20
Shares Outstanding281,349,950
10 Day Avg. Volume18,335,083
30 Day Avg. Volume12,702,500
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)0.94
Price to Sales (P/S)1.09
P/FCF Ratio-8.06
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue1.53
Enterprise Value/Gross Profit2.84
Enterprise Value/Ebitda29.14
Forecast
1Y Price Target
$26.15Price Target Upside30.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)0.7
Revenue Forecast (FY)$3.44B
MiniMed Group, Inc. Business Overview & Revenue Model
Company Description
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, c...
MiniMed Group, Inc. Earnings Call Summary
Earnings Call Date:Sep 01, 2026
(Q1-2027)
| % Change Since: |
Next Earnings Date:Jun 09, 2027
Earnings Call Sentiment Positive
The call was strongly positive, with robust organic revenue growth, accelerating U.S. performance, broad international momentum, improving operating metrics, multiple pipeline milestones delivered ahead of schedule and raised revenue guidance. Reported EBITDA margin and free cash flow were affected by foreign exchange and stand-alone separation activities, while Simplera's mix remains a current-year gross-margin headwind, but management reaffirmed full-year EBITDA margin guidance and described the underlying business performance as strong.Positive Updates
Strong First-Quarter Organic Revenue Growth
Q1 revenue was $843 million, up 15.8% organically and ahead of expectations. Growth benefited from an extra fiscal-calendar week by approximately 4 to 6 points; excluding that benefit, organic growth was in the low double digits versus 8.7% in Q4.
Negative Updates
Reported EBITDA Margin Was Reduced by Specific Items
Q1 adjusted EBITDA was $83 million, resulting in a 9.9% adjusted EBITDA margin. The margin included an approximately 230-basis-point impact from an approximately $8 million pull-forward of planned investment and a $12 million nonoperational foreign-exchange remeasurement charge; excluding those items, adjusted EBITDA margin would have been 12.2%.
Read all updates
Q1-2027 Updates
Positive
Negative
Strong First-Quarter Organic Revenue Growth
Q1 revenue was $843 million, up 15.8% organically and ahead of expectations. Growth benefited from an extra fiscal-calendar week by approximately 4 to 6 points; excluding that benefit, organic growth was in the low double digits versus 8.7% in Q4.
Read all positive updates
Company Guidance
MiniMed raised its fiscal 2027 organic revenue growth outlook to approximately 10.5% from prior guidance of approximately 10%, including the expected 1 to 1.5 percentage points benefit from the Q1 extra week, and reaffirmed fiscal 2027 adjusted EBITDA margin guidance of approximately 16%; the company expects EBITDA margins to improve from Q1 levels throughout fiscal '27, with a larger portion of the improvement occurring in the second half of the year, while it expects organic revenue growth in both the U.S. and international markets to be more comparable to the underlying growth rates delivered in Q1, excluding the extra week, and continues to expect growth in both new pumps sold and CGM attachment rates. MiniMed expects to begin the European launch of Flex in November of this year, a full U.S. launch of Fit by summer next year with manufacturing capacity to support 20,000 patients at launch, Vivera on the U.S. market in the second half of calendar year '27, and a pivotal trial for its next-generation extended wear sensor in October.MiniMed Group, Inc. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Apr 2026 | Apr 2025 | Apr 2024 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 3.22B | 3.10B | 2.71B | 2.47B |
| Gross Profit | 1.74B | 1.68B | 1.52B | 1.44B |
| EBITDA | 169.00M | 205.00M | 107.00M | 59.00M |
| Net Income | -329.00M | -331.00M | -250.00M | -112.00M |
Balance Sheet | ||||
| Total Assets | 4.72B | 4.63B | 4.20B | 4.09B |
| Cash, Cash Equivalents and Short-Term Investments | 207.00M | 298.00M | 11.00M | 54.00M |
| Total Debt | 59.00M | 145.00M | 11.00M | 8.00M |
| Total Liabilities | 1.10B | 1.02B | 870.00M | 646.00M |
| Stockholders Equity | 3.62B | 3.61B | 3.33B | 3.45B |
Cash Flow | ||||
| Free Cash Flow | -316.00M | -420.00M | -53.00M | -107.00M |
| Operating Cash Flow | -105.00M | -197.00M | 140.00M | 41.00M |
| Investing Cash Flow | -211.00M | -233.00M | -193.00M | -157.00M |
| Financing Cash Flow | 514.00M | 716.00M | 10.00M | 112.00M |
MiniMed Group, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | $3.32B | 23.50 | 12.94% | 1.23% | 7.19% | 32.91% | |
82 Outperform | $2.32B | 21.89 | 9.57% | ― | 15.88% | 25.01% | |
70 Outperform | $2.89B | 9.99 | 150.20% | ― | 19.52% | 1337.90% | |
69 Neutral | $4.77B | 23.95 | 15.83% | ― | 5.95% | 5.33% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | $5.42B | -16.09 | -9.11% | ― | ― | ― | |
48 Neutral | $2.45B | -17.74 | 405.63% | ― | -4.42% | 44.67% |
* General Sector Average
MMED
MiniMed Group, Inc.
19.25
0.76
4.11%
ADUS
Addus Homecare
124.34
6.41
5.44%
OPCH
Option Care Health
31.85
5.65
21.54%
BKD
Brookdale Senior Living
10.27
1.02
11.03%
NHC
National Healthcare
212.16
92.16
76.80%
AVAH
Aveanna Healthcare Holdings
13.26
3.92
41.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.